| mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0058 |
0.9 |
| mRNA |
selumetinib:navitoclax (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.006 |
0.9 |
| mRNA |
CAL-101 |
GDSC1000 |
pan-cancer |
AAC |
0.0048 |
0.9 |
| mRNA |
isonicotinohydroxamic acid |
CTRPv2 |
pan-cancer |
AAC |
0.0075 |
0.9 |
| mRNA |
BRD8958 |
CTRPv2 |
pan-cancer |
AAC |
0.0062 |
0.9 |
| mRNA |
AZ628 |
GDSC1000 |
pan-cancer |
AAC |
-0.0072 |
0.9 |
| mRNA |
BRD-A02303741:carboplatin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0058 |
0.9 |
| mRNA |
GSK429286A |
GDSC1000 |
pan-cancer |
AAC |
-0.0046 |
0.9 |
| mRNA |
BRD-K41334119 |
CTRPv2 |
pan-cancer |
AAC |
-0.011 |
0.9 |
| mRNA |
momelotinib |
CTRPv2 |
pan-cancer |
AAC |
0.0052 |
0.9 |